CytRx Names New CFO
Los Angeles-based CytRx, a biopharmaceuticals firm which is developing small molecule drugs for the treatment of ALS, said earlier this week that it has appointed Mitchell K. Fogelman as the firm's CFO. Fogelman replaces Matthew Natalizio, who has left the firm. Fogelman was most recently at International Aluminum Corporation, and also has been at PricewaterhouseCoopers LLP. ALS (Amyotrophic lateral sclerosis) is often referred to as Lou Gehrig's disease. CytRx says that it is planning to enter a Phase IIb clinical trial pending FDA clearance of its lead compound.
posted on Friday, September 14, 2007 (Link to more information)

Related companies:

Related stories:
> CytRx Names New Board Member
> CytRx Chairman Passes Away
> CytRx Raises $40M Via Term Loan
> CytRx Acquires Innovive Pharmaceuticals
> CytRx Sells Assets To Orphazyme Home